{"paper_id":"503d565a-f41a-49ad-8131-cf36ff25dfb7","body_text":"Page 1/14\nInvestigation of Vascular Endothelial Growth Factor(VEGF) Polymorphism in Patients With Idiopathic HeavyMenstrual Bleeding\nİ kbal Kaygusuz  (  ikbal_cekmen@yahoo.com )\nDepartment of Obstetrics and Gynecology, VM Medicalpark Ankara Private Hospital, Yüksek İ htisas University,\nAnkara, Turkey https://orcid.org/0000-0002-5635-505X\nNur Semerci Gündüz \nDepartment of Medical Genetics, Ankara Yıldırım Beyazıt University, Denizli, Turkey\nResearch Article\nKeywords: Excessive menstrual bleeding, polymorphism, vascular endothelial growth factor, VEGF gene\nPosted Date: May 5th, 2021\nDOI: https://doi.org/10.21203/rs.3.rs-459616/v1\nLicense:   This work is licensed under a Creative Commons Attribution 4.0 International License.   Read Full\nLicense\nVersion of Record: A version of this preprint was published at Archives of Gynecology and Obstetrics on September\n8th, 2021. See the published version at https://doi.org/10.1007/s00404-021-06225-1.\n\nPage 2/14\nAbstract\nPurpose: To investigate whether there is a relationship between the VEGF gene polymorphisms and idiopathic heavy\nmenstrual bleeding (HMB-E).\nMethods: 65 patients diagnosed with HMB-E according to the FIGO classication system and 65 female healty\nvolunteers were included in the study. Detection of rs699947 (-2578C>A), rs1570360 (-1154G>A), rs2010963\n(+405G>C), rs3025039 (+936C>T), rs25648 (c534C>T)  polymorphic regions of the VEGF gene was performed by Next\nGeneration DNA Sequencing method.\nResults: the -2578C>A polymorphic region CC, CA+AA genotypes, and C allele, as well as the -1154G>A polymorphic\nregion AA genotype, and A allele were associated with increased risk of HMB-E (all p<0.05). However, no statistically\nsignicant difference was found between the the patient group and the control group in terms of genotype and allele\ndistributions in the 405G>C, +936C>T, c534C>T polymorphic regions (all p>0.05). While the -2578/-1154/+405/c534\nAGGC haplotype decreased the risk of HMB-E, CAGC haplotype was found to increase the risk of HMB-E.\nConclusion: VEGF -2578C>A and -1154G>A polymorphisms were signicantly associated with the risk of HMB-E in the\nTurkish population. \nIntroduction\nHeavy menstrual bleeding (HMB) is an important health problem dened as menstruation at regular intervals but with\nexcessive ow and duration. Clinically, it is dened as a blood loss of more than 80 ml per cycle. It is a common\ngynecological problem among women of reproductive age and accounts for more than 20% of outpatient visits to\ngynecologists [1]. Although HMB is often associated with uterine pathology (e.g., broid, polyp, adenomyosis,\ncarcinoma), abnormal blood clotting or disruption of hormonal regulation, approximately 50% of HMB cases occur in\nthe absence of recognized uterine pathology [2,3], suggesting a defect in the cellular processes and regulatory\nmechanisms of menstruation. Such idiopathic HMB of endometrial origin (HMB-E) has been estimated to account for\n9-14% of gyneco logical outpatient visits [4,5].\nHMB can lead to iron deciency anemia. Current treatment options often compromise fertility, and may require\nhysterectomy in patients who do not respond to the treatments [6]. Another problem is increased maternal morbidity\nand mortality for pregnant women who has HMB-associated anemia. Heavy bleeding can affect daily activities. Need\nfor long-term medication, the side effects of these therapies, and the intolerance can cause psychological and social\ndiscomfort. Also for numerous female individuals, problems related to employment have led to the designation of\nHMB as a public health problem [4].\nDisturbance of endometrial angiogenesis is one of several proposed underlying mechanisms that have been\nsuggested to play a role in HMB [4,5]. In the formation of functional and stable micro vessels, covering the luminal\nsurface of endothelial tubes with mesenchymal pericytes is an important step. The pericytes interact tightly and\nadhere to the endothelial cells with the pores in the basal layer [7]. Pericytes may induce angiogenesis with Vascular\nEndothelial Growth Factor (VEGF) production which stimulates endothelial cell proliferation and tube formation.\nPrevious studies have shown that The biopsy specimens of women with HMB have revealed that number of\ncapillaries expressing VEGF-A and its receptors (VEGFR-1 and VEGFR-2) were signicantly higher in patients with\nHMB compared to healthy controls [1]. It is known that glandular luminal surfaces of patients with HMB are wider and\nthis nding is highly correlated with overexpression of VEGF-A and VEGFR-1 [8]. It is suggested that the mesenchymal\npericytes acting on the basis of angiogenesis may contribute to the vascular fragility. This leads to excessive blood\n\nPage 3/14\nloss due to extensive endothelial cell gaps and abnormal vascular remodeling as a result of inappropriate coverage of\nthe laminal surface of endothelial tubes [8,9].\nIn the literature, there is no study investigating the VEGF polymorphism in patients with idiopathic HMB-E. The\nevidence of the presence of VEGF polymorphism in patients with HMB-E may provide new opportunities for future\nresearch and treatment options. Thus, patients and doctors will avoid the risks of unnecessary surgeries. We therefore\nplanned to investigate the relationship between VEGF polymorphism and idiopathic HMB-E.\nMaterials And Methods\nOur study is a cross-sectional study conducted from February 2019 to March 2020. It was approved by the Ankara\nYıldırım Beyazıt University Yenimahalle Training and Research Hospital Clinical Research Ethics Committee on the\ndate of 29.01.2019 and with the decision number of 2019/01/01 and complied with the Helsinki Declaration,\nincluding current revisions and the Good Clinical Practice guidelines.\nPower analysis of the study showed that 128 patients were needed to gain 80% power when α  error was set at 0.05, β\nerror at 0.05, and effect size at 0.50.\nA total of 65 patients between the ages of 18-45 who were admitted with the complaint of abnormal uterine bleeding\nand diagnosed with idiopathic HMB according to the FIGO Classication System [10]  and 65 voluntary women with\nregular menstruation were included in the study. All participants were informed about the study and consent forms\nwere signed.\nThe participants were selected according to the dened inclusion criteria: 18 to 45 years old, having a regular\nmenstrual cycle between 24 - 38 days, not using hormonal or intrauterine contraception for at least three months prior\nthe study, no abnormal ultrasonographic or hysteroscopic ndings, not pregnant and not lactating.\nWomen were excluded from the study if they had a uterine pathology (such as polyp, adenomyosis, leiomyoma,\nmalignancy, hyperplasia), had a history of signicant medical problems (such as coagulopathies, hypothyroidism,\nhyperprolactinemia, Polycystic ovary syndrome, endometriosis), smokers, taken any medicines that increases the\ntendency to bleeding.\nFor patient selection according to these criteria all participants were evaluated based on a complete medical,\ngynecological and obstetric history and gynecological examination with ultrasound assessment. Additionally,\nhysteroscopy or dilatation and curettage was performed in the presence of suspicion of endometrial pathology.\nMenstrual blood loss was evaluated with Pictorial Blood loss Assessment Chart (PBAC) which has a a positive\npredictive value of 85.9% in diagnosing menorrhagia and with a good correlation to alkaline hematin method [11,12].\nSelf-evaluated PBAC consists of diagrams representing different soiled pads or tampons each day and pads were\nscored according to the degree of staining and the size of the clots on it. Women with a PBAC score > 100 were\nincluded in the HMB group and healthy, ovulating women with a PBAC score < 100 were considered in the control\ngroup.\nSingle nucleotide polymorphism (SNP) selection: Five highly plausible candidate SNPs in the VEGF gene were\nselected including rs699947 (-2578C>A, in the promoter region), rs1570360 (-1154G>A, in the promoter region)\nrs2010963 (+405G>C, at 5′UTR), rs3025039 (+936C>T, at 3'UTR), rs25648 (c534C>T, at exon1) and checked in\nEnsemble, dbSNP database.\n\nPage 4/14\nPeripheral venous blood samples were collected from all subjects and transferred to EDTA tubes. Samples were\nstored frozen at -20°C until they were studied.\nLaboratory studies were carried out in the INTERGEN Genetic and Rare Diseases Diagnosis Research and Application\nCenter.\nDNA extraction and genotyping: DNA extraction was performed from 200 µl peripheral blood with spin column\nmethod using HibriGen Blood DNA isolation kit ( İ stanbul, Turkey). The isolates were measured with Nanodrop 1000\n(Thermo Inc.) microvolume spectrophotometer and the study continued with samples containing 10 ng / µl and more.\nPrimer design was made for PCR amplication of all coding region and exon-intron junction regions of VEGFA gene\nand 4 polymorphisms (rs699947, rs1570360, rs2010963, rs3025039). Primers, amplicon size and usage purposes are\nshown in table 1.\nAmplication of the regions was achieved by using the isolated DNA and the designed primers in the PCR reaction.\nAmplication eciency was evaluated by visualizing the reaction results with 2% agarose gel electrophoresis. PCR\npools were created by combining the PCRs of each sample and then puried by NucleoFast® 96 PCR kit (MACHEREY-\nNAGEL GmbH). The puried samples were quantitated by a spectrophotometer (Nanodrop N1000, Thermo Inc.). The\namount of DNA was determined and diluted to 5 ng / µl.\nDetection of polymorphisms was performed by NGS (Next Generation DNA Sequencing) method using Miseq device\n(Illumina Inc. San Diego, CA, USA). Standardized samples were prepared for next generation sequencing using the\nNextera XT sample preparation kit (Illumina Inc.). DNA Library preparations were made according to the determined\ninstructions. A sample worksheet le was created to introduce the study to the device. All of the prepared samples\nwere loaded into the sample loading compartment in the Miseq Reagent Kit v2 2x150 (MS-102-2002, Illumina Inc.)\ncartridge. After all the preparations and controls were made, the Miseq device was started. Approximately 24 hours\nlater, study results were taken and analyzed. Alignment of the obtained readings was done with Miseq Reporter\n(illumina Inc.) software on human genome hg19 version. Analysis of the aligned bam les was performed using IGV\n2.3 (Broad Institute) software.\nStatistical Analyses\nContinuous variables were rst inspected for normality of statistical distribution graphically and by Shapiro–Wilk test.\nData were reported as mean ± standard deviation (SD), median with interquartile ranges (IQRs) or numbers and\npercentages, as appropriate. The data were analyzed using the Student’s t test, Mann–Whitney test or chi square test\nto determine the signicance of the differences between the groups. The Chi-square test was used to assess the\nvariation in each SNP frequency from Hardy–Weinberg equilibrium (HWE). Logistic regression analysis models were\nused to calculate the odds ratio (OR) and 95% condence interval (CI), thereby assessing the effect of genotypes on\nHMB risk. These analyzes were calculated with IBM SPSS 25 and the epitools package in R 3.6.1 program. The\nhaplotype of VEGF polymorphisms was analyzed by using SHEsis. The linkage disequilibrium of genotype and allele\npairs was calculated via the Haploview version 4.2 (Broad Institute, Cambridge, MA, USA).Statistical signicance was\nset at P ≤  0.05.\nResults\nBaseline characteristics\n\nPage 5/14\nThe baseline characteristics of the subjects are summarized on Table 2. There were no differences in age, Body Mass\nIndex (BMI), marital status, gravidity, parity, age at menarche, length of menstrual cycle between the analyzed groups.\nCompared with the control group, as aspected the patients in HMB group presented signicant increases in menses\nduration and PBAC score.\nGenotype and allele distribution of VEGF polymorphisms\nThe genotype frequency distribution of the selected population were found to be compatible in Hardy-Weinberg\nequilibrium (p > 0.05), suggesting it represents the population.\nAs shown in Table 3, the risk of having HMB in individuals with the VEGF gene −2578A>C polymorphic region CC\ngenotype was 3.05 times higher, the AC + CC genotype was 2.35 times higher compared with the AA genotype, C allele\nwas 1.75 times higher compared with A allele (CC vs AA, OR = 3.05, 95% CI = 1.11-8.84, p = 0.025; AC + CC vs AA, OR =\n2.35, 95% CI = 0.97-6.0, p = 0.051; C vs A, OR = 1.75, 95% CI = 1.07-2.88, p = 0.024). In comparison with the −1154G>A\npolymorphic region GG genotype, AA genotype is related to 3.49 times higher risk of HMB and in comparison with G\nallele, A allele is related to 1.74 times higher risk og HMB (AA vs GG, OR=3.49, % 95 CI=0.89-18.10, P = 0.06; A vs G,\nOR=1.74, % 95 CI =1.01-3.01, P = 0.04). However, the genotype and allele frequency distributions of rs2010963,\nrs3025039 and rs25648 were not statistically different between groups  (all p > 0.05).\nHaplotype analysis for the association between VEGF gene polymorphisms and HMB risk\nVEGF gene polymorphisms in linkage disequilibrium analysis including four SNP (-2578C>A, -1154G>A, +405G>C and\n534C>T) revealed one SNP block (Figure 1).\nWe detected four main haplotypes with frequencies greater than 0.03. CACC, AGGC, CAGC, AAGT. These haplotypes\nwere analyzed with the online software SHEsis and compared between the HMB and the control group (Table 4). The\nAGGC haplotype was found to be statistically signicantly lower in the HMB group with a percentage of 23.8% than in\nthe control group 38.5% (OR = 0.505, 95% CI = 0.295-1.517, p = 0.012). The CAGC haplotype was statistically\nsignicantly higher in the HMB group with 25.4% and 9.2% in the control group (OR = 3.387, 95% CI 0.481-2.116, p =\n0.0005). As a result, it was concluded that AGGC haplotype decreased the risk of HMB and CAGC haplotype increased\nthe risk of HMB.\nDiscussion\nIn this study we aimed to investigate the signicance of SNPs of the VEGF gene (rs699947 (-2578C>A), rs1570360\n(-1154G>A) rs2010963 (+405G>C), rs3025039 (+936C>T), rs25648 (c534C>T) in HMB. We have found increased risk\nfor HMB in patients with CC, AC+CC genotype, and C allele of the -2578C>A polymorphic region and AA genotype and\nA allele of the -1154G>A polymorphic region (p < 0.05). However, we have not observed any associations between\nHMB and other three candidate polymorphisms of +405G>C, +936C>T, and c534C>T (p > 0.05).\nIn the literature, we have not encountered any studies emphasising on the relationship between SNPs and HMB.\nNevertheless, there are several studies investigating the effect of VEGF gene polymorphisms in cardiovascular\ndiseases, essential hypertension, certain cancer types, psoriasis, and endometriosis. Although being a unique study\nrepresents strength of our work, it also enabled us to discuss or compare our results with similar papers. Therefore, we\ncompared our ndings with articles about endometriosis, which denes a gynecologic disease that endometrial tissue\nis present outside the uterus. \n\nPage 6/14\nPerini et al. [13] evaluated -2578C>A, −460T>C, −1154G>A, +405G>C, and +936C>T polymorphisms in 182 Brazilian\nwomen with endometriosis and reported that variant allele -1154A was had signicant relationship with\nendometriosis. They found AA genotype in 9.3% of patients and 1.9% of controls while the frequency of GA+AA\ngenotype was 44.1% in patients and 30.2% in controls, and frequency of A allele was 26.7% in patient group and\n16.0% in controls (p < 0.05). In our study, the AA genotype was found in 56.9% of patients and 38.5% of controls while\nthe frequency of GA+AA genotype was 95.4% for patients and 87.7% for controls and the frequency of A allele was\n76.1% in HMB patients and 61.5% in controls (p < 0.05). Perini et al. [13] reported an approximate two-fold increased\nrisk for endometriosis in individuals with GA+AA genotype of the -1154G>A polymorphic region and an approximate 6-\nfold increased risk for AA genotype.  Similarly, we have observed an approximate two-fold increased risk for HMB in\nindividuals with GA+AA genotype (p > 0.05), an approximate 3.5 fold increase in AA genotype (p = 0.06), and an\napproximate two fold increase in case of harbouring A allele (p = 0.04). Although these two studies presents distinct\ngenotype and allele frequencies, individuals having A allele in 1154G>A polymorphic region have been found to have\nsignicantly increased risk for the dened diseases. \nOn the other hand, in another study from Northern China on 344 women with endometriosis and 360 healthy controls\nby Liu et al. [14], AA genotype of the -1154G>A polymorphic region was alleged to decrease the risk of endometriosis.\nThe frequency of AA genotype of the -1154G>A polymorphic region was 1.7% in patients and 5.8% in controls while\nthe frequency of harboring A allele was 16.1% in patients and 22.2% in controls concluding a statistically signicant\nreduction of endometriosis risk in case of A allele of -1154G>A polymorphism.\nPerini at al. [13] did not report an association between endometriosis and VEGF gene -2578C>A polymorphisms.\nSimilarly, in our study the frequency of CC genotype of -2578C>A polymorphism was 38.5% in patients and 24.6% in\ncontrols, and the frequency of AC + CC genotype was 86.2% in patients and 72.3% in controls. Despite being more\nfrequent in patients, the difference was not statistically signicant (p = 0.083). As for the C allele, the frequency was\n62.3% in patients and 48.5% in controls which established a statistically signicant difference (p < 0.05). Therefore,\nwe have found an approximate 3 fold increased risk for HMB in individuals with CC genotype of the -2578C>A\npolymorphic region and an approximate 2 fold increased risk in AC+CC genotype and C allele. Also, Liu et al. [14]\nreported frequencies of AA, CA, and CC genotypes and A allele frequency of -2578C>A polymorphic region in patient\nand control groups respectively; 3.2% - 8.1%; 32.0% - 36.4%, and 64.8% - 55.6%, 19.2% - 26.3% concluding a\nstatistically signicant difference in terms of genotype and allele harbouring (p <0.004, p = 0.002 respectively).\nSimilarly,  having C allele has been associated with HMB in our study as in case with endometriosis.\nWith regards to the +405G>C, +936C>T polymorphic region our results suggest no signicant effect on the\nsusceptibility to HMB. It is noteworthy that our results are consistent with Perini’s study [13] and Zhao and colleagues\n[15] which consist a larger number (958 cases and 959 controls) of Australian women. Similarly Liu et al. [14] found\nthat the + 936C>T polymorphic region does not have a signicant relationship with the risk of developing\nendometriosis.\nThe main reason for these inconsistent results may be the differences between ethnic groups. For example, the\nEnsembl database shows that the frequency of the VEGF -2578 A allele was 27.2% with the CHB (Han Chinese in\nBeijing), 34.1% with AMR (American), and 45.5% with CEU (Utah Residents with Northern and Western European\nAncestry).\nIn the literature, we found two studies from our country evaluating the effect of VEGF gene +405G>C polymorphism\non endometriosis risk with controversial results. Altınkaya et al. [16] evaluated the genotype frequencies of VEGF\n+405G>C polymorphic regions on 98 endometriosis patients and 94 controls. They detected GC genotype in 58.2% of\n\nPage 7/14\npatients and 10.6% of controls and G allele in 45.4% of patients and 5.3% of controls. They suggested that GC\ngenotype and G allele may be associated with the advanced grade endometriosis risk in the Turkish population. In\nanother study from Turkey, Attar et al. [17.] also proposed that CC genotype of +405G>C polymorphisms may be\nrelated to endometriosis whereas G allele has a protective role against endometriosis. The small sample sizes impede\nwith reecting data of the whole Turkish population and may partially explain the conicting results.\nThe meta-analyses also yielded conicting results. In a meta-analysis evaluating 14 eligible studies on a total of 3313\nendometriosis patients and 3393 controls, VEGF gene -1154G>A polymorphic region GA genotype and A allele and\n-2578C>A polymorphic region CC genotype and C allele were found to reduce endometriosis risk whereas +936C>T\npoymorphic region CT genotype and T allele increased the risk similar to our results on HMB [18]. No effect of the\n+405G>C polymorphism was reported in line with our ndings. On the contrary, Jiang et al. [19] stated that VEGF +\n405G>C and + 936C>T SNPs may be associated with the risk of endometriosis in their meta-analysis, in which they\ninvestigated 9 studies including 1610 endometriosis patients and 1643 control cases.\nThe most important limitation of the current study is the small sample size which can also be held responsible for the\ncontroversial results in other studies in the literature. Besides, the facts that these studies have been performed on\ndistinct ethnic groups and different diseases and having identied various haplotypes may have led to the conicting\nresults. These diverse results suggest that disease tendency may stem from not solely a single polymorphism but a\ncombined effect of polymorphisms and that haplotype effect may play a more signicant role in disease tendency\nthan single polymorphisms.\nIn our study in the examination of the -2578C>A, -1154G>A,+405G>C and 534C> T polymorphic regions of the VEGF\ngene we have identied 4 haplotypes: CACC (38.1%), AGGC (31.2%), CAGC (17.3%), AAGT (12.3%). AGGC haplotype\nwas less prevalent in HMB patients (23.8% vs 38.5%) while CAGC haplotype was more frequent in the HMB group\n(25.4% vs 9.2%). Perini et al. [13] emphasized that CCGG haplotype derived from four polymorphisms (-2578C>A /\n-460T>C / -1154G>A / + 405G>C) has a protective effect against the development of endometriosis (3% in cases, 6.7%\nin the control group). Liu et al. [14] stated that the VEGF gene -460C>T -1154G>A, -2578C>A regions included CAA, TAA\nand TAC haplotypes can signicantly reduce the risk of developing endometriosis, and the CAC haplotype can\nsignicantly increase the risk of developing endometriosis. The polymorphic regions included in the studies produced\ndifferent linkage disequilibrium results and different haplotypes were obtained in each study making it dicult to\ncompare study results.\nOur study on VEGF gene polymorphisms in Turkish women with HMB suggests increased risk for C allele, CC, and\nAC+CC genotypes of −2578A>C polymorphic region, A allele, AA genotype, and CAGC haplotype of the −1154G>A\npolymorphic region whereas protective role of the AGGC haplotype. However, further studies with a larger sample size\nare required to gure out a more certain association. \nDeclarations\nAuthor Contribution\nİ  Kaygusuz: Project development, Data collection,  Data analysis, Manuscript writing, editing\nN Semerci Gündüz: Project development, reduction, editing\nI. Ethical approval: The study was approved by the Ankara Yıldırım Betazıt University Human Ethical Committee\nII. Funding details (In case of Funding): No funding\n\nPage 8/14\nIII.    Conict of interest: The authors declare that they have no conict of interest.\nIV. Informed Consent: Signed informed consent was obtained from all patients before starting study.\nReferences\n1. Mints M, Blomgren B, Falconer C, Fianu-Jonasson A, Palmblad J (2005) Microvascular density, vascular\nendothelial growth factor A, and its receptors in endometrial blood vessels in patients with menorrhagia. Fertil\nSteril 84(3):692-700. https://doi.org/10.1016/j.fertnstert.2005.03.065\n2. Elkilani OA, Soliman MA (2017) Angiogenesis mediators in women with idiopathic heavy menstrual bleeding. Int\nJ Gynaecol Obstet 136(3):280-284. https://doi.org/10.1002/ijgo.12068\n3. Biswas Shivhare S, Bulmer JN, Innes BA, Hapangama DK, Lash GE (2018) Endometrial vascular development in\nheavy menstrual bleeding: altered spatio-temporal expression of endothelial cell markers and extracellular matrix\ncomponents. Hum Reprod 33(3):399-410. https://doi.org/10.1093/humrep/dex378\n4. Kuzmina N, Palmblad J, Mints M (2011) Predictive factors for the occurrence of idiopathic menorrhagia: evidence\nfor a hereditary trait. Mol Med Rep 4(5):935-939. https://doi.org/10.3892/mmr.2011.514\n5. Andersson E, Zetterberg E, Vedin I, Hultenby K, Palmblad J, Mints M (2015) Low pericyte coverage of endometrial\nmicrovessels in heavy menstrual bleeding correlates with the microvessel expression of VEGF-A. Int J Mol Med\n35(2):433-438. https://doi.org/10.3892/ijmm.2014.2035\n. Mansour D, Hofmann A, Gemzell-Danielsson K (2021) A Review of Clinical Guidelines on the Management of Iron\nDeciency and Iron-Deciency Anemia in Women with Heavy Menstrual Bleeding. Adv Ther 38(1):201-225.\nhttps://doi.org/10.1007/s12325-020-01564-y\n7. Fraser IS, Critchley HO, Munro MG, Broder M, Writing Group for this Menstrual Agreement Process (2007) A\nprocess designed to lead to international agreement on terminologies and denitions used to describe\nabnormalities of menstrual bleeding. Fertil Steril 87(3):466-476. https://doi.org/10.1016/j.fertnstert.2007.01.023\n. Mints M, Hultenby K, Zetterberg E, Blomgren B, Falconer C, Rogers R, Palmblad J (2007) Wall discontinuities and\nincreased expression of vascular endothelial growth factor-A and vascular endothelial growth factor receptors 1\nand 2 in endometrial blood vessels of women with menorrhagia. Fertil Steril 88(3):691-697.\nhttps://doi.org/10.1016/j.fertnstert.2006.11.190\n9. Mints M, Blomgren B, Palmblad J (2010) Expression of angiopoietins 1, 2 and their common receptor tie-2 in\nrelation to the size of endothelial lining gaps and expression of VEGF and VEGF receptors in idiopathic\nmenorrhagia. Fertil Steril 94(2):701-707. https://doi.org/10.1016/j.fertnstert.2009.03.042\n10. Munro MG, Critchley HO, Broder MS, Fraser IS, FIGO Working Group on Menstrual Disorders (2011) FIGO\nclassication system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of\nreproductive age. Int J Gynaecol Obstet 113(1):3-13. https://doi.org/ 1016/j.ijgo.2010.11.011\n11. Higham JM, O’Brien PM, Shaw RW (1990) Assessment of menstrual blood loss using a pictorial chart. Br J\nObstet Gynaecol 97:734-739. https://doi.org/10.1111/j.1471-0528.1990.tb16249.x\n12. Zakherah MS, Sayed GH, El-Nashar SA, Shaaban MM (2011) Pictorial blood loss assessment chart in the\nevaluation of heavy menstrual bleeding: diagnostic accuracy compared to alkaline hematin. Gynecol Obstet\nInvest 71: 281-284. https://doi.org/10.1159/000320336\n13. Perini JA, Cardoso JV, Berardo PT, Vianna-Jorge R, Nasciutti LE, Bellodi-Privato M, Machado DE, Abrão MS (2014)\nRole of vascular endothelial growth factor polymorphisms (-2578C>A, -460 T>C, -1154G>A, +405G>C and\n\nPage 9/14\n+936C>T) in endometriosis: a case-control study with Brazilians. BMC Womens Health 14:117. https://doi.org/\n1186/1472-6874-14-117\n14. Liu Q, Li Y, Zhao J, Sun DL, Duan YN, Wang N, Zhou RM, Kang S (2009) Association of polymorphisms -1154G/A\nand -2578C/A in the vascular endothelial growth factor gene with decreased risk of endometriosis in Chinese\nwomen. Hum Reprod 24(10):2660-2666. https://doi.org/10.1093/humrep/dep208\n15. Zhao ZZ, Nyholt DR, Thomas S, Treloar SA, Montgomery GW (2008) Polymorphisms in the vascular endothelial\ngrowth factor gene and the risk of familial endometriosis. Mol Hum Reprod 14(9):531-538.\nhttps://doi.org/10.1093/molehr/gan043\n1. Altinkaya SO, Ugur M, Ceylaner G, Ozat M, Gungor T, Ceylaner S (2011) Vascular endothelial growth factor +405\nC/G polymorphism is highly associated with an increased risk of endometriosis in Turkish women. Arch Gynecol\nObstet 283(2):267-72. https://doi.org/10.1007/s00404-009-1344-1\n17. Attar R, Agachan B, Kuran SB, Toptas B, Eraltan IY, Attar E, Isbir T (2010) Genetic variants of vascular endothelial\ngrowth factor and risk for the development of endometriosis. In Vivo 24(3):297-301.\n1. Li YZ, Wang LJ, Li X, Li SL, Wang JL, Wu ZH, Gong L, Zhang XD (2013) Vascular endothelial growth factor gene\npolymorphisms contribute to the risk of endometriosis: an updated systematic review and meta-analysis of 14\ncase-control studies. Genet Mol Res 12(2):1035-44. https://doi.org/10.4238/2013.April.2.20\n19. Jiang Y, Tang JY, Wu Y, Zhao TF (2012) Vascular endothelial growth factor gene polymorphisms and the risk of\nendometriosis: a systematic review. Zhonghua Fu Chan Ke Za Zhi 47(3):179-84.\nTables\nTable 1. Primers, amplicon size and usage purposes\n\nPage 10/14\nPrimer Orientation Sequencing Genotyping Ampliconsize (bp) Sequence (5'-3')\nVEGFA_SNP2_F Forward Exon 1 SNP 2\nSNP 3\nSNP 5\n1500 CGGATGGGTAATTTTCAGGCTGTG\nVEGFA_1R Revers CCTCCCCCTGCACCTAAGACGAC\nVEGFA_2F Forward Exon 2 - 468 GGGAAGTGTGGGGAAGGTACAGG\nVEGFA_2R Revers CTTCCCCTTCCTCCCCACAGTTC\nVEGFA_3F Forward Exon 3 - 433 GAAGCTCCAAAGAGTGGCATTACAG\nVEGFA_3R Revers ACCATACCTCCCCTGTGCAACTC\nVEGFA_4-5F Forward Exon 4\nExon 5\n- 975 AGGAGTCAGGGTGAAGCCTAGAGAG\nVEGFA_4-5R Revers CACTAGCCCTAGAGCCATCATCCTG\nVEGFA_6F Forward Exon 6 - 398 AGAGACCACCTGCCTCCTGACAC\nVEGFA_6R Revers TCTACCCGTTGGTGCCAATTAGTG\nVEGFA_7F Forward Exon 7 - 429 CTGTAGCGCTCGGATCCTTCCAG\nVEGFA_7R Revers ACCAGGCAGGCAGCTAGAAACTGAG\nVEGFA_8F Forward Exon 8 SNP 4 463 CCTTCCTGTCCTCTCTGCTCTTATGG\nVEGFA_8R Revers ATCTTCCGGGCTCGGTGATTTAG\nVEGFA_SNP1_F Forward - SNP 1 250 CTGGAGCGTTTTGGTTAAATTGAGG\nVEGFA_SNP1_R Revers CCCCATCCCATTCTTGCATATAGG\n \nTable 2: Baseline characteristics of study subjects\n\nPage 11/14\nVariables HMB group (n=65) Control group (n=65) t/z c2 p\nAge (year) 30.58 ± 7.06 29.08 ± 6.56 t=1.261 0.210\nBody Mass Index (kg/m2) 22.35 ± 2.57 22.77 ± 2.65 t=0.923 0.358\nMarital status        \nMarried 43 (% 66.2) 40 (% 61.5) c2 =0.300 0.584\nUnmarried 22 (% 33.8) 25 (% 38.5)\nGravidity 1 (2) 1 (1) Z=-1.361 0.180\nParity 1 (2) 1 (2) Z=-1.185 0.290\nAge at menarche (year) 13 (2) 13 (1) Z=-1.311 0.190\nMenses duration (days) 7 (2.5) 5 (2) Z=5.339 <0.001*\nLength of Menstrual cycle (day) 28 (3) 28 (2) Z=0.320 0.749\nPBAC score 258 (246) 50 (44) Z=9.937 <0.001\nAbbreviations: PBAC, Pictorial Blood Loss Assessment Chart\nData are mean ± SD, median (IQR) or numbers (n) and percentages (%)\nt= Student’s t test, Z=Mann–Whitney U-test, c2 = Chi-square\n* p values ≤  0.05 were considered statistically signicant\n \nTable 3. Logistic regression analysis of associations between VEGF polymorphisms and risk of HMB\n\nPage 12/14\n  AMK-E grup,\nn = 65 (%)\nKontrol grup,\nn = 65 (%)\nOR (95% CI) p\nrs699947 (−2578A>C)      \nAA 9 (13.8) 18 (27.7) Referans  \nAC 31 (47.7) 31 (47.7) 1.97 (0.77-5.29) 0.15\nCC 25 (38.5) 16 (24.6) 3.05 (1.11-8.84) 0.03*\nAC+CC 56 (86.2) 47 (72,3) 2.35 (0.97-6.0) 0.05*\nA Alel 49 (37.7) 67 (51.5) Referans  \nC Alel 81 (62.3) 63 (48.5) 1.75 (1.07-2.88) 0.02*\nrs1570360  (−1154G>A)      \nGG 3 (4.6) 10 (15.4) Referans  \nGA 25 (38.5) 30 (46.2) 2.13 (0.53-11.20) 0.26\nAA 37 (56.9) 25 (38.5) 3.49 (0.89-18.10) 0.06*\nGA+AA 62 (95.4) 57(87.7) 2.07 (0.56-10.32) 0.26\nG Alel 31 (23.8) 50 (38.4) Referans  \nA Alel 99 (76.1) 80 (61.5) 1.74 (1.01-3.01) 0.04*\nrs2010963 (+405G>C)      \nCC 9 (13.8) 9 (13.8) Referans  \nCG 30 (46.2) 33 (50.8) 0.91 (0.31-2.66) 0.85\nGG 26 (40.0) 23 (35.4) 1.12 (0.37-3.41) 0.82\nCG+GG 56 (86.2) 56 (86.2) 0.99 (0.33-2.78) 1.00\nC Alel 48 (36.9) 51 (39.2) Referans  \nG Alel 82 (63.1) 79 (60.8) 1.10 (0.66-1.82) 0.70\nrs3025039 (+936C>T)      \nCC 49 (75.4) 43 (66.2) Referans  \nCT 15 (23.1) 20 (30.8) 0.66 (0.29-1.45) 0.29\nTT 1 (1.5) 2 (3.1) 0.46 (0.01-5.98) 0.49\nCT+TT 16 (24.6) 22 (33.9) 0.64 (0.29-1.37) 0.24\nC Alel 113 (86.9) 106 (81.5) Referans  \nT Alel 17 (13.1) 24 (18.5) 0.66 (0.33-1.30) 0.23\nrs25648 (c.534C>T)      \nCC 49 (75.4) 51 (78.5) Referans  \nCT 16 (24.6) 12 (18.5) 0.72 (0.31-1.68) 0.18\n\nPage 13/14\nTT 0 2 (3.1) - -\nCT+TT 16 (24.6) 14 (21.6) 0.84 (0.37-1.90) 0.68\nC Alel 114 (87.7) 114 (87.7) Referans  \nT Alel 16 (12.3) 16 (12.3) 1 (0.47-2.12) 1.00\n   Abbreviations: OR, odds ratio; CI, condence interval.\n   * p values ≤  0.05 were considered statistically signicant\n \nTable 4. Haplotype distributions of VEGF gene polymorphisms rs699947, rs1570360, rs2010963, and rs25648\nHaplotype Frequency (%) HMB group, n=65 (%) Control group, n=65 (%) P OR (95% CI)\nCAAC 38.1 48 (36.9) 51 (39.2) 0,737 0.918 (0.555-1.517)\nAGGC 31.2 31 (23.8) 50 (38.5) 0,012* 0.505 (0.295-0.864)\nCAGC 17.3 33 (25.4) 12 (9.2) 0,0005* 3.387 (1.659-6.917)\nAAGT 12.3 16 (12.3) 16 (12.3) 0.981 1.009 (0.481-2.116)\nAbbreviations: OR, odds ratio; CI, condence interval.\n* p values ≤  0.05 were considered statistically signicant\n \nFigures\n\nPage 14/14\nFigure 1\nLinkage disequilibrium plot created by Haploview 4.2","source_license":"CC0","license_restricted":false}